Weak momentum in sales in the US, headwinds from pricing pressure, and lack of meaningful product launches led pharma giant Dr. Reddy's Laboratories Ltd. to report a low single digit growth in the bottom line in the December quarter, which fell short of the Street's expectations. However, the company's top line grew in mid-teens during the quarter, driven by revenues from its recently acquired Nicotine Replacement Therapy portfolio, and sales in India and emerging markets.
Share this Story:
